Pfizer Net Profit And Net Margin From 2012 To 2016

This report provides the last five years net profit and net margin of Pfizer Inc (PFE) from 2012 to 2016. Pfizer reported a total net income of $7.2 billion during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. Pfizer net profit margin was 13.7% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Pfizer Net Profit From 2012 To 2016

Here are the net profit and the net profit margin details of Pfizer during the last five years:

  • Pfizer reported a total net profit of $14.6 billion and a net profit margin of 26.7% during 2012.
  • Pfizer reported a total net profit of $22 billion and a net profit margin of 42.7% during 2013.
  • Pfizer reported a total net profit of $9.1 billion and a net profit margin of 18.4% during 2014.
  • Pfizer reported a total net profit of $7 billion and a net profit margin of 14.2% during 2015.
  • Pfizer reported a total net profit of $7.2 billion and a net profit margin of 13.7% during 2016.

Why Analyze Net Profit Margin?

Net Profit Margin (also known as net margin) is one of the most commonly used profitability ratio. Net profit margin represents the money a company makes on every dollar of sales. It is computed by dividing the total net income of a company with its total revenues. A positive net margin means the company generated more revenues than its costs and expenses. A negative net margin means the company spent more on its costs and expenses than the revenues it generated.

Net profit margin analysis is important for a number of reasons. First, it helps in understanding the extent of a company's profits or losses. A high positive net margin means the company can keep more money for itself and can possibly invest it into the business to generate more revenues in the future. A high negative net margin means the company is losing a lot of money and its survival will be difficult unless the company grows revenues at a faster rate or cuts its costs and expenses. Common cost cutting measures include outsourcing, employee layoffs, and business units shutdowns or divestitures. Second, a company's historical profit margin analysis along with its revenue forecast analysis can help in forecasting the future profits of a company. Third, a company's net margin comparison with the other companies in the same industry or the industry average can help identify the operationally most efficient companies. A comparison of net margins of companies in different industries can help identify the most profitable business models.

Pfizer Ranking

With $52.8 billion revenues, Pfizer ranked number 50 in the R&P Research list of top-3000 public companies in the US by revenues during 2016. Each one of the top-3000 companies generated more than $50 million of annual revenues during 2016.

The top-20 companies in the US by revenues during 2016 were:

  1. Walmart ($482.1 billion)
  2. ExxonMobil ($226.1 billion)
  3. Berkshire Hathaway ($223.6 billion)
  4. Apple ($215.6 billion)
  5. McKesson ($190.9 billion)
  6. UnitedHealth Group ($184.8 billion)
  7. CVS Health ($177.5 billion)
  8. General Motors ($166.4 billion)
  9. AT&T ($163.8 billion)
  10. Ford Motor ($151.8 billion)
  11. AmerisourceBergen ($146.8 billion)
  12. Amazon ($136 billion)
  13. Verizon ($126 billion)
  14. General Electric ($123.7 billion)
  15. Cardinal Health ($121.5 billion)
  16. Costco ($118.7 billion)
  17. Walgreens Boots Alliance ($117.4 billion)
  18. Chevron ($114.5 billion)
  19. Kroger ($109.8 billion)
  20. Express Scripts Holding ($100.3 billion)

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

For example, Healthcare sector group is comprised of Life Sciences sector and Healthcare Services sector. Life Sciences sector is comprised of following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. Healthcare Services sector is comprised of following industries: Drug Stores, PBM and Distributors; Healthcare Payers; Healthcare Providers; Medical Software; Healthcare Research Services.

Pfizer is associated with Healthcare Sector Group, Life Sciences Sector, and Pharmaceuticals Industry.

With $52.8 billion revenues, Pfizer ranked number 12 of all the companies in the US Healthcare sector group. There were a total of 290 public companies in the US Healthcare sector group that had revenues greater than $50 million during 2016.

The top-10 companies in the US Healthcare sector group by revenues during 2016 were:

  1. McKesson ($190.9 billion)
  2. UnitedHealth Group ($184.8 billion)
  3. CVS Health ($177.5 billion)
  4. AmerisourceBergen ($146.8 billion)
  5. Cardinal Health ($121.5 billion)
  6. Walgreens Boots Alliance ($117.4 billion)
  7. Express Scripts Holding ($100.3 billion)
  8. Anthem ($84.9 billion)
  9. J&J ($71.9 billion)
  10. Aetna ($63.2 billion)

Healthcare sector group is comprised of the following sectors: Life Sciences; Healthcare Services.

With $52.8 billion revenues, Pfizer ranked number 2 of all the companies in the US Life Sciences sector. There were a total of 197 public companies in the US Life Sciences sector that had revenues greater than $50 million during 2016.

The top-10 companies in the US Life Sciences sector by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Gilead Sciences ($30.4 billion)
  5. Medtronic ($28.8 billion)
  6. Abbvie ($25.6 billion)
  7. Amgen ($23 billion)
  8. Eli Lilly ($21.2 billion)
  9. Abbott Laboratories ($20.9 billion)
  10. Bristol Myers Squibb ($19.4 billion)

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

With $52.8 billion revenues, Pfizer ranked number 2 of all the companies in the US Pharmaceuticals industry. There were a total of 49 public companies in the US Pharmaceuticals industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Pharmaceuticals industry by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Eli Lilly ($21.2 billion)
  5. Abbott Laboratories ($20.9 billion)
  6. Bristol Myers Squibb ($19.4 billion)
  7. Allergan ($14.6 billion)
  8. Shire ($11.4 billion)
  9. Mylan ($11.1 billion)
  10. Valeant Pharmaceuticals ($9.7 billion)

Companies Segmentation

To identify and analyze high/low growth or most/least profitable similar-size companies in different sectors or industries, R&P research classifies all companies into different segments based upon their revenues, revenue growth, and net profit margins.

Based upon their annual revenues, the companies are classified into one of the following four segments:

  1. Mega companies, having revenues greater than $50 billion.
  2. Very Large companies, having revenues between $10 billion and $50 billion.
  3. Large companies, having revenues between $1 billion and $10 billion.
  4. Mid-size companies, having revenues between $50 million and $1 billion.

With $52.8 billion revenues, Pfizer was in the Mega companies revenue segment during 2016. There were a total of 54 companies in the Mega companies revenue segment during 2016.

Based upon their annual revenue growth, the companies are classified into one of the following eight segments:

  1. Very High positive growth companies, having annual revenue growth greater than 50%.
  2. High positive growth companies, having annual revenue growth between 20% and 50%.
  3. Medium positive growth companies, having annual revenue growth between 5% and 20%.
  4. Low positive growth companies, having annual revenue growth between 0% and 5%.
  5. Low negative growth companies, having annual revenue growth between -5% and 0%.
  6. Medium negative growth companies, having annual revenue growth between -20% and -5%.
  7. High negative growth companies, having annual revenue growth between -50% and -20%.
  8. Very High negative growth companies, having annual revenue growth less than -50%.

With 8.1% revenue growth year-over-year, Pfizer was in the Medium positive revenue growth segment during 2016. There were a total of 876 companies in the Medium positive revenue growth segment during 2016. Of the US top-3000 companies, 1985 (nearly two-third of the total) had positive revenue growth and 1015 (nearly one-third of the total) had negative revenue growth during 2016.

Based upon their annual net profit margin, the companies are classified into one of the following eight segments:

  1. Very High positive margin companies, having net profit margin greater than 50%.
  2. High positive margin companies, having net profit margin between 20% and 50%.
  3. Medium positive margin companies, having net profit margin between 5% and 20%.
  4. Low positive margin companies, having net profit margin between 0% and 5%.
  5. Low negative margin companies, having net profit margin between -5% and 0%.
  6. Medium negative margin companies, having net profit margin between -20% and -5%.
  7. High negative margin companies, having net profit margin between -50% and -20%.
  8. Very High negative margin companies, having net profit margin less than -50%.

With a net margin of 13.7%, Pfizer was in the Medium positive net profit margin segment during 2016. There were a total of 1086 companies in the Medium positive net profit margin segment during 2016. Of the US top-3000 companies, 2244 (nearly three-fourth of the total) had positive net profit margin and 756 (nearly one-fourth of the total) had negative net profit margin during 2016.

Company Business Summary

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; collaboration with Merck and Corning for pharma glass packaging project; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Data Source

The chart and the data on this page are sourced from the R&P Research Industry Intelligence Platform. The platform provides the key financial metrics for all the public companies in the United States. The platform empowers users to compare last five or 15 years financial data of a company with the other companies or the industry averages. This benchmarking exercise yields powerful insights that can drive better business decisions.


Industry Peers and Competitors of Pfizer

J&J (JNJ) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Johnson & Johnson with $72 billion revenues in the year 2016 was the number 1 Pharmaceuticals company. Read this report to know the top competitors of J&J and identify growth and cost optimization opportunities of J&J

Merck (MRK) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Merck & Co., Inc. with $40 billion revenues in the year 2016 was the number 3 Pharmaceuticals company. Read this report to know the top competitors of Merck and identify growth and cost optimization opportunities of Merck

Eli Lilly (LLY) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Lilly Eli & Co with $21 billion revenues in the year 2016 was the number 4 Pharmaceuticals company. Read this report to know the top competitors of Eli Lilly and identify growth and cost optimization opportunities of Eli Lilly

Abbott Laboratories (ABT) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Abbott Laboratories with $21 billion revenues in the year 2016 was the number 5 Pharmaceuticals company. Read this report to know the top competitors of Abbott Laboratories and identify growth and cost optimization opportunities of Abbott Laboratories

Bristol Myers Squibb (BMY) Business Analysis – Analyze Historical Performance, Strategic...

Bristol Myers Squibb Co with $19 billion revenues in the year 2016 was the number 6 Pharmaceuticals company. Read this report to know the top competitors of Bristol Myers Squibb and identify growth and cost optimization opportunities of Bristol Myers Squibb

Allergan (AGN) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Allergan Plc with $15 billion revenues in the year 2016 was the number 7 Pharmaceuticals company. Read this report to know the top competitors of Allergan and identify growth and cost optimization opportunities of Allergan

Revenues Analysis

Pfizer (PFE) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Pfizer Inc (PFE) from 2012 to 2016. Pfizer generated a total of $52.8 billion revenues during 2016. Pfizer reported a revenue growth of 8.1% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Pfizer (PFE) Revenues And Revenue Growth From 2002 To 2016

This report provides the last fifteen years revenues and revenue growth of Pfizer Inc (PFE) from 2002 to 2016. Pfizer generated a total of $52.8 billion revenues during 2016. Pfizer reported a revenue growth of 8.1% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Pfizer (PFE) Revenue Growth Comparison With Industry Growth From 2012 To...

This report provides a comparison of Pfizer Inc (PFE) revenue growth with Pharmaceuticals industry growth during the last five years from 2012 to 2016. Pfizer reported a revenue growth of 8.1% year-over-year during 2016. The Pharmaceuticals industry growth was 7.7% year-over-year during 2016. Pfizer growth was faster than the industry during 2016.

Profit Analysis

Pfizer (PFE) Net Profit And Net Margin From 2012 To 2016

This report provides the last five years net profit and net margin of Pfizer Inc (PFE) from 2012 to 2016. Pfizer reported a total net income of $7.2 billion during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. Pfizer net profit margin was 13.7% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Pfizer (PFE) Net Profit And Net Margin From 2002 To 2016

This report provides the last fifteen years net profit and net margin of Pfizer Inc (PFE) from 2002 to 2016. Pfizer reported a total net income of $7.2 billion during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. Pfizer net profit margin was 13.7% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Pfizer (PFE) Net Profit Margin Comparison With Industry From 2012 To...

This report provides a comparison of Pfizer Inc (PFE) net profit margin with Pharmaceuticals industry net profit margin during the last five years from 2012 to 2016. Pfizer reported a net profit margin of 13.7% during 2016. The Pharmaceuticals industry net profit margin was 15.8% during 2016. Pfizer was less profitable than the industry during 2016.

Cost & Expenses Analysis

Pfizer (PFE) Cost of Sales (COGS) Analysis From 2012 To 2016

This report provides the last five years cost of sales (COGS) analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer spent a total of $12.3 billion on COGS during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer spent 23.3% of its total revenues on COGS during 2016. The cost of sales (COGS) numbers are for the fiscal year ending in December.

Pfizer (PFE) Research & Development (R&D) Spending Analysis From 2012 To...

This report provides the last five years research and development (R&D) expenses of Pfizer Inc (PFE) from 2012 to 2016. Pfizer spent a total of $7.9 billion on research and development (R&D) activities during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer spent 14.9% of its total revenues on R&D activities during 2016. The R&D spending numbers are for the fiscal year ending in December.

Pfizer (PFE) Sales, Marketing, General & Administrative (SG&A) Spending Analysis From...

This report provides the last five years sales, marketing, general & administrative (SG&A) expenses of Pfizer Inc (PFE) from 2012 to 2016. Pfizer spent a total of $14.8 billion on sales, marketing, general, and administrative (SG&A) activities during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer spent 28.1% of its total revenues on SG&A activities during 2016. The SG&A spending numbers are for the fiscal year ending in December.

Working Capital Analysis

Pfizer (PFE) Inventory Spending Analysis From 2012 To 2016

This report provides the last five years inventory spending analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer invested a total of $6.8 billion on inventories during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer invested 12.8% of its total revenues on inventories during 2016. The inventory numbers are for the fiscal year ending in December.

Pfizer (PFE) Accounts Receivable (A/R) Analysis From 2012 To 2016

This report provides the last five years Accounts Receivable (A/R) analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer invested a total of $8.2 billion on accounts receivable during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer invested 15.6% of its total revenues on accounts receivable during 2016. The accounts receivable numbers are for the fiscal year ending in December.

Pfizer (PFE) Accounts Payable (A/P) Analysis From 2012 To 2016

This report provides the last five years Accounts Payable (A/P) analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer invested a total of $6.5 billion on accounts payable during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer invested 12.3% of its total revenues on accounts payable activities during 2016. The accounts payable numbers are for the fiscal year ending in December.

Asset Management Analysis

Pfizer (PFE) Property, Plant & Equipment (PP&E) Investment Analysis From 2012...

This report provides the last five years property, plant & equipment (PP&E) investment analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer invested a total of $13.3 billion on property, plant & equipment (PP&E) activities during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer invested 25.2% of its total revenues on PP&E activities during 2016. The PP&E investment numbers are for the fiscal year ending in December.

Pfizer (PFE) Intangible Assets Analysis From 2012 To 2016

This report provides the last five years Intangible assets analysis of Pfizer Inc (PFE) from 2012 to 2016. Pfizer invested a total of $107.1 billion on Intangible assets during 2016. Pfizer generated a total of $52.8 billion revenues during 2016. As a percentage of revenues, Pfizer invested 202.7% of its total revenues on intangible assets during 2016. The Intangible asset numbers are for the fiscal year ending in December.

Got Questions?

Get in touch with us. We are happy to help!

Contact Us:


sales@revenuesandprofits.com